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Abstract
We assessed the comparative efficacy of empirical therapy with
beta-lactam plus macrolide vs. beta-lactam plus doxycycline for
the treatment of community-acquired pneumonia (CAP) among
patients in the Australian Community-Acquired Pneumonia Study.
Both regimens demonstrated similar outcomes against CAP due
to either ‘atypical’ (Chlamydophila, Legionella or Mycoplasma spp.)
or typical bacterial pathogens.
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During the last decade there has been debate about the use
of combinations of antimicrobial agents in the treatment of
community-acquired pneumonia (CAP), with many
international guidelines recommending a beta-lactam plus a
macrolide (or possibly doxycycline) for severe CAP [1,2].
However, given the emerging rates of macrolide resistance
in Streptococcus pneumoniae and Mycoplasma species [3,4] and
the lack of head-to-head comparisons of clinical efficacy of
doxycycline vs. macrolides when combined with a beta-
lactam, we assessed the comparative efficacy of the two drug
combinations: beta-lactam plus macrolide (BLA-M; erythro-
mycin, roxithromycin, clarithromycin or azithromycin) vs.
beta-lactam plus doxycycline (BLA-D) among patients
recruited to the Australian Community-Acquired Pneumonia
Study (ACAPS), a large prospective study of CAP [5].
ACAPS has been described elsewhere, including a detailed
description of inclusion and exclusion criteria, microbiologi-
cal methods and analyses [5]. Choice of empirical antimicro-
bial therapy was determined by the managing physicians, with
records indicating high (82.4%) concordance with the Austra-
lian Antibiotic Guidelines [6]. ‘Atypical’ bacterial pathogens
were defined as those belonging to the Legionella, Chlamydo-
phila or Mycoplasma species, while all other bacterial patho-
gens were considered to be ‘typical’, as previously described
[5].
Of the various clinical measures studied in ACAPS, the
following demographic and primary clinical outcome mea-
sures were assessed: age (mean ± SD), on-admission Pneu-
monia Severity Index (PSI) risk class (mild/moderate
CAP = PSI £ 3; severe CAP = PSI ‡ 4; [7]), the need for
invasive respiratory or vasopressor support (IRVS) in the
intensive care unit (ICU) during the inpatient stay, clinical
deterioration (defined as the need to change antimicrobial
therapy to broader spectrum agents), time to clinical stability
(defined as at least 24 h of temperature £37.2C and respira-
tory rate £24 breaths/min), inpatient length of stay (LOS)
and 30-day mortality. Patients in the study who required
IRVS or died within 48 h of commencing antibiotics were
noted to allow further analysis.
CAP aetiology was defined as being due to ‘atypical’ or
‘typical’ pathogens regardless of whether a viral pathogen
was also identified. Patients with only a viral pathogen or no
pathogen identified were compared for both groups but
were excluded from further analysis. Only patients who
received empirical combination therapy with either BLA-D
or BLA-M were assessed.
Both treatment groups were compared in terms of
demographic features, typical vs. atypical aetiology and CAP
severity (PSI and need for IRVS). Statistical comparisons
were undertaken using Student’s t-test or chi-squared (or
Fishers exact) test where appropriate. Where data were not
normally distributed, a Mann–Whitney rank sum test was
used. A p-value of <0.05 was considered significant.
Among the 885 patient episodes assessed in the ACAP
study, 858 episodes (96.9%) received empirical combination
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therapy (178 (20.7%) BLA-D; 680 (79.2%) BLA-M). A com-
parison of demographic, aetiology, CAP severity and out-
come data is shown in Table 1. Overall, patients in the two
treatment groups were similar in terms of age (p 0.44) and
clinical PSI severity on admission (p 0.54), but a greater pro-
portion of BLA-M recipients required IRVS (p < 0.001) and
subsequently had a longer time to clinical stability (p 0.006)
and a longer inpatient LOS (p < 0.001; Table 1).
Demographics and outcome features of the subgroup of
patients with ‘typical’ and ‘atypical’ bacterial CAP are shown
in Table 1. Similar demographic findings were noted for
BLA-M patients, who had a higher rate of IRVS (p 0.02) if
they had CAP due to ‘typical’ pathogens but a similar rate if
the CAP was due to ‘atypical’ pathogens (p 0.07). Rates of
clinical deterioration, time to clinical stability, inpatient LOS
and mortality were similar between treatment groups for
CAP episodes due to ‘typical’ bacterial pathogens, but for
CAP due to ‘atypical’ pathogens BLA-D was associated with
a shorter inpatient LOS (p < 0.001; Table 1). These primary
clinical outcome findings, in particular shorter LOS, did not
change substantially when patients who required IRVS very
soon (<48 h) after admission (i.e. before the effect of antimi-
crobial therapy could be expected) were excluded or if only
patients with PSI £ 3 (mild-moderate CAP) were analysed
(p < 0.001; see Table 2).
Combination therapy with BLA-M has been recommended
by many authors and guidelines due to perceived superiority
over BLA monotherapy, particularly among patients with
bacteraemic pneumococcal CAP [8,9]. Possible immunomo-
dulatory effects of macrolides or the presence of undetected
infection with ‘atypical’ bacterial pathogens are some of the
proposed reasons for any observed superiority [8–10]. Few
studies have assessed the relative efficacy of BLA-D vs. BLA-
M in such patients, which is notable because doxycycline is
TABLE 1. Demographic and clinical features of all CAP episodes with ‘typical’ and ‘atypical’ subgroups treated with BLA-M or
BLA-D
Clinical features
Overall (n = 855) ‘Typical’ bacterial pathogens ‘Atypical’ bacterial pathogens
BLA-Da
(n = 178)b
BLA-Mc
(n = 680)d
p-value BLA-De
(n = 32)
BLA-Mf
(n = 147)
p-value BLA-Dg
(n = 27)
BLA-Mh
(n = 90)
p-value
Age (years), mean ± SD 66.3 ± 19.0 65.0 ± 20.1 0.44 72.8 ± 12.6 67.8 ± 18.4 0.15 50.0 ± 23.7 54.6 ± 22.6 0.36
Male sex (%) 100 (56.2) 419 (61.6) 0.22 16 (50.0) 90 (61.2) 0.33 19 (70.3) 55 (61.1) 0.52
CAP severity: No. with severe
(PSI ‡4) CAP (%)
93 (52.2) 375 (55.1) 0.54 20 (62.5) 97 (66.0) 0.87 9 (33.3) 37 (41.1) 0.40
No. requiring IRVS (%) 2 (1.1) 92 (13.5) <0.001# 1 (3.1) 29 (19.7) 0.02 # 0 (0) 12 (13.3) 0.07 #
No. with early clinical deterioration (%) 26 (14.6) 144(21.2) 0.06 5 (15.6) 36 (24.5) 0.36 # 4 (14.8) 21 (23.3) 0.43 #
30-day mortality (%) 5 (2.8) 43 (6.3) 0.10 # 2 (6.3) 13 (8.8) 1.00# 1 (3.7) 3 (3.3) 1.00 #
Median days to clinical stability (range) 2 (0–7) 2 (0–22) 0.006* 2 (0–4) 2 (0–20) 0.40* 2 (0–4) 2 (0–17) 0.07*
Median no. days length of stay (range) 5 (0–26) 6 (0–78) <0.001* 5 (3–35) 6 (0–78) 0.21* 3 (0–7) 6 (0–70) <0.001*
aBLA-D = beta-lactam + doxycycline.
bOf the 178 BLA-D patient episodes, 28 episodes caused by viral pathogens and 91 of unknown cause were included.
cBLA-M = beta-lactam + macrolide.
dOf the 680 BLA-M patient episodes, 66 episodes caused by viral pathogens and 377 of unknown cause were included.
eOf the 32 BLA-D patient episodes, 19 episodes were caused by S. pneumoniae (59.4%).
fOf the 147 BLA-M patient episodes, 89 episodes were caused by S. pneumoniae (60.5%).
gOf the 27 BLA-D patient episodes, 6 episodes were caused by Legionella sp. (22.2%), 21 episodes were caused by Mycoplasma sp.(77.8%).
hOf the 90 BLA-M patient episodes, 24 episodes were caused by Legionella sp. (26.7%), 51 episodes were caused by Mycoplasma sp. (56.7%) and 15 were caused by Chlamydo-
philia sp. (16.6%).
#Fisher’s exact test was performed.
*Mann–Whitney rank sum was performed.
TABLE 2. Summary of clinical features of the two subgroups of patients: exclusion of patients who required IRVS or who died
within 48 h and patients with PSI £ 3
Clinical
features
Patients who deteriorated £48 h excluded Patients with PSI £ 3
‘Typical’ bacterial pathogens ‘Atypical’ bacterial pathogens ‘Typical’ bacterial pathogens ‘Atypical’ bacterial pathogens
BLA-D
(n = 31)
BLA-M
(n = 124)
p-value BLA-D
(n = 26)
BLA-M
(n = 80)
p-value BLA-D
(n = 12)
BLA-M
(n = 50)
p-value BLA-D
(n = 18)
BLA-M
(n = 53)
p-value
Age (years),
mean ± SD
73.6 ± 11.8 70.0 ± 17.7 0.29 49.2 ± 23.7 53.8 ± 22.4 0.37 63.9 ± 13.7 53.1 ± 19.4 0.09 37.2 ± 17.4 41.8 ± 18.2 0.33
Male sex (%) 16 (51.6) 76 (61.3) 0.33 18 (69.2) 47 (58.8) 0.34 5 (41.6) 24 (48.0) 0.76 11 (61.1) 25 (47.1) 0.41
Median days to
clinical stability
(range)
2 (0–4) 2 (0–11) 1.00 2 (0–4) 2 (0–14) 0.12 3 (0–4) 3 (0–20) 0.69 2 (0–4) 2 (0–14) 0.11
Median no. days
length of stay
(range)
5 (3–30) 6 (0–42) 0.64 3.5 (0–7) 5 (0–70) <0.001 5.5 (2–35) 5 (0–57) 0.64 3 (0–7) 5 (0–70) <0.001
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usually not considered to exhibit immunomodulatory effects
and, in some regions, is associated with lower rates of resis-
tance among invasive pneumococcal isolates than macrolides
[11,12]. Furthermore, for some ‘atypical’ bacterial pathogens
such as Chlamydophia psittaci, doxycycline may be clinically
superior to macrolides [13]. Thus, our findings of at least
comparable outcomes in patients treated with BLA-D vs.
BLA-M for CAP due to ‘typical’ bacterial pathogens are nota-
ble. Among patients with CAP due to ‘atypical’ bacterial
pathogens, BLA-D was at least comparable in outcomes and
possibly superior in terms of reduced LOS (p < 0.001).
Our study has some important limitations. Similar to many
studies of BLA-M, our study was retrospective and non-ran-
domized, with the empirical antibiotic selection determined
by the treating clinicians. In fact, high concordance with the
Australian CAP guidelines was noted, such that patients
assessed as having severe CAP were often prescribed BLA-M
in preference to BLA-D [6], resulting in relatively small num-
bers in the BLA-D group. This may have resulted in some
confounding that cannot fully be statistically corrected for,
such that a totally balanced comparison of outcomes cannot
be achieved from our data. Nevertheless, the fact that BLA-
D treatment appears to display at least similar outcomes to
BLA-M for both ‘typical’ and ‘atypical’ CAP is notable for
non-severe CAP, given the dearth of other published data on
this topic.
Despite these limitations, we believe our findings will be
of interest to clinicians who appreciate the cost differences
between doxycycline and macrolides and the high rates of
emerging macrolide resistance among key respiratory patho-
gens in many regions [3,4,14,15]. This study reinforces that
doxycycline is an appropriate alternative to macrolides, in
combination with a beta-lactam for mild to moderate CAP.
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